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Abstract
Objective To assess strategies for advice on analgesia and steam
inhalation for respiratory tract infections.
Design Open pragmatic parallel group factorial randomised controlled
trial.
Setting Primary care in United Kingdom.
Participants Patients aged ≥3 with acute respiratory tract infections.
Intervention 889 patients were randomised with computer generated
random numbers in pre-prepared sealed numbered envelopes to
components of advice or comparator advice: advice on analgesia (take
paracetamol, ibuprofen, or both), dosing of analgesia (take as required
v regularly), and steam inhalation (no inhalation v steam inhalation).
Outcomes Primary: mean symptom severity on days 2-4; symptoms
rated 0 (no problem) to 7 (as bad as it can be). Secondary: temperature,
antibiotic use, reconsultations.
Results Neither advice on dosing nor on steam inhalation was
significantly associated with changes in outcomes. Compared with
paracetamol, symptom severity was little different with ibuprofen (adjusted
difference 0.04, 95% confidence interval −0.11 to 0.19) or the
combination of ibuprofen and paracetamol (0.11, −0.04 to 0.26). There
was no evidence for selective benefit with ibuprofen among most
subgroups defined before analysis (presence of otalgia; previous duration
of symptoms; temperature >37.5°C; severe symptoms), but there was
evidence of reduced symptoms severity benefit in the subgroup with
chest infections (ibuprofen −0.40, −0.78 to −0.01; combination −0.47;
−0.84 to −0.10), equivalent to almost one in two symptoms rated as a
slight rather than a moderately bad problem. Children might also benefit
from treatment with ibuprofen (ibuprofen: −0.47, −0.76 to −0.18;
combination: −0.04, −0.31 to 0.23). Reconsultations with new/unresolved
symptoms or complications were documented in 12% of those advised
to take paracetamol, 20% of those advised to take ibuprofen (adjusted
risk ratio 1.67, 1.12 to 2.38), and 17% of those advised to take the
combination (1.49, 0.98 to 2.18). Mild thermal injury with steam was
documented for four patients (2%) who returned full diaries, but no
reconsultations with scalding were documented.
Conclusion Overall advice to use steam inhalation, or ibuprofen rather
than paracetamol, does not help control symptoms in patients with acute
respiratory tract infections and must be balanced against the possible
progression of symptoms during the next month for a minority of patients.
Advice to use ibuprofen might help short term control of symptoms in
those with chest infections and in children.
Trial registration ISRCTN 38551726.
Introduction
Acute respiratory tract infections are the commonest acute
condition managed in primary care, and control of symptoms
is central for patients and parents of affected children.1 2Advice
to use antipyretics or analgesics is perhaps the commonest
advice given in the National Health Service (NHS)3 but use is
often suboptimal even for conditions with both fever and pain
(such as otitis media).4
A previous trial in primary care showed that ibuprofen is more
effective than paracetamol alone for resolution of fever in
children,5 6 and this was supported by more recent systematic
reviews.7 8 The effect sizes, however, were modest (particularly
for children); most trial data provide short term assessment, and
limited assessment of symptom control or progression; and the
study designs are normally tightly controlled efficacy designs,
often in secondary care—all of which makes it difficult to apply
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findings in primary care, where most advice on analgesia is
given. There are also concerns about inhibiting the
inflammatory/febrile process9 and about the adverse effects of
ibuprofen on cardiovascular risk in adults.10 Alternate dosing
of paracetamol and ibuprofen is common andwasmore effective
in children in one trial,11 but the trial was a less pragmatic
efficacy design, and there is little evidence in adults. A recent
systematic review concluded that theremight bemarginal benefit
in combining analgesics but also noted short term effects of
marginal clinical importance and secondary care settings.12 The
National Institute for Health and Clinical Excellence (NICE)
cautioned against combined use because of renal/hepatic
complications,3 although the evidence was largely from case
studies in a secondary care setting.
Although advice to use steam is commonly given in primary
care, the evidence of effectiveness is limited13 as trials have
been small. There have been some reports of burns,14 which are
rare and have occurred in children using boiling water after poor
instruction, so the NHS direct website recommended that doctors
advise parents to “sit in the bathroom with a hot shower
running.”
We estimated the effectiveness of commonly used strategies
for advice in analgesia and steam inhalation.
Method
Design and randomisation
We carried out a pragmatic randomised factorial trial in a
primary care setting in patients with respiratory tract infection.
We examined the difference in the effectiveness between three
different antipyretic regimens: ibuprofen, paracetamol, and
combined ibuprofen and paracetamol; whether regular
antipyretic dosing gives significantly better control of symptoms
and temperature than “as required” dosing; and whether regular
inhalation with steam improves symptom control. Further details
are in the appendix.
A statistician independent of the study team coordinated the
randomisation, which was stratified by antibiotic prescribing
strategy (immediate antibiotics or delayed antibiotics). Patients
were randomised to one of 12 advice groups defined by three
factors (three drug groups × two dosing groups × two steam
groups) in a factorial design, with computer generated random
number tables to determine one of 12 advice slips contained in
sealed numbered envelopes. The advice factors were:
• Drugs: advice to use paracetamol or ibuprofen or combined
paracetamol and ibuprofen alternating
• Dosing advice to use drugs regularly four times a day for
at least three days then ad lib or to use on an as required
basis, both as per guidance in the British National
Formulary (BNF, 59th edition). The doses used each day
were recorded in a diary
• Steam—advice to inhale with steam for at least 15 minutes
(five minutes three times a day) or asked not to use steam.
The number of times steam inhalation was done was
recorded in a daily diary.
A key logistic issue in complex pragmatic factorial trials is the
avoidance of errors in delivery of the intervention. We made it
simple to execute randomisation as the clinician took the next
pack off the shelf that contained pre-randomised advice sheets
(that is, there was no requirement (hence minimal error) in
finding and using the correct advice sheets). With careful
attention to practitioner equipoise this method of randomisation
to different advice strategies has proved successful
previously,4 15 16 and there was no evidence of subversion either
from the order of envelope use or patients’ characteristics.
General practitioners were asked to complete non-recruitment
logs and also a questionnaire at the end of the study documenting
reasons for non-recruitment of eligible patients and for eligible
patients who declined.
Inclusion criteria
We included patients aged ≥3 presenting to a general practitioner
or nurse in primary care with a respiratory tract infections
diagnosed by the health professional (acute cold; influenza; sore
throat; otitis media; sinusitis; croup; cough/lower respiratory
tract infection). There was no clinical selection other than the
inclusion/exclusion criteria: practitioners were asked to include
consecutive patients whenever feasible.
Exclusion criteria
We excluded patients with asthma (unless it was not sensitive
to ibuprofen or aspirin); peptic ulcer; hypersensitivity to
analgesics; inability to complete outcomes (such as visually
impairment, psychosis, severe depression); conditions requiring
hospital admission (such as meningitis, severe pneumonia,
epiglottitis, Kawasaki disease, etc); or immunodeficiency; and
pregnant or breastfeeding women.
Outcomes
Primary outcome
Our primary outcome was symptom control documented as
mean symptom severity measured at the end of each day,
averaged over days two to four of a two week symptom diary
(the first few days are when symptoms of all respiratory tract
infections are at their worst4 16). The diary was completed by
patients (and/or children, with their parents helping as necessary)
until symptoms returned to normal, using previously validated
formats16 17 for rating symptoms (0=no problem, 6=as bad as it
could be for feeling generally unwell, sleep disturbance, fever,
interference with normal activities, sore throat, cough, short of
breath, facial/sinus pain, earache, and runny/blocked nose).
Though we have reported symptom resolution (duration of
symptoms rated moderately bad or worse from the diary or brief
questionnaire18), this was not specified initially as an outcome
as duration differs according to the particular respiratory
infection.19
Patients were telephoned (on day two to three) to check for any
problems with diary completion. If we had not received a diary
after two weeks, we sent one mailed reminder and then phoned
as necessary to document outcomes using a brief questionnaire,
which we have shown to be reliable.15
Secondary outcome measures
Secondary outcomes included:
• Side effects (rash, diarrhoea, vomiting, abdominal pain)
documented in the diary; scalding was not included in the
initial protocol but was included in subsequent protocol
revisions
• Mean morning and evening temperature reading with
Tempadot (3M, Bracknell) thermometers (orally where
possible)
• Antibiotic use documented in the diary (which was not
initially specified as an outcome for this component of the
trial)
• Return visit with new or worsening symptoms or
complications of intervention,18 defined as a return with a
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symptom or diagnosis of respiratory tract infection recorded
with a structured proforma by a member of the research
team. “Complications” were defined as a new consultation
documented in the notes within 28 days with otitis media,
sinusitis, pneumonia, quinsy, cervical adenitis, meningitis,
or septicaemia. This outcome was not specified as an
effectiveness outcome in the protocol but is routinely
collected to document harms.
Sample size calculation
We calculated our required sample size for α=0.05 and β=0.2
using the NQuery multiple group sample size programme. We
assumed an SD of 1.1 for our primary outcome.15-17 Our
assumption was that each factor was a separate
“experiment”—that is, that factors were independent and that
the comparisons of interest were within each factor. For the
analgesic factor we assumed that either ibuprofen or the
combined group could have symptom control 0.5 SD better than
the paracetamol only group. We need 228 patients to allow for
12 groups and 80% follow-up, or 504 patients for 0.33 SD
(equivalent to one in three rating symptoms mild versus
moderate, agreed by previous consensus as a modest effect16).
The limiting element of the sample size calculation, however,
was for the antibiotic component of the study (reported
elsewhere): we estimated 72 patients per group or 450 altogether
in the no and delayed prescribing groups, allowing for 20% loss
to follow-up and assuming 15% use of antibiotics in the no
antibiotic group, and that antibiotic use ranged between 20%
and 35% in the delayed groups (20%, 25%, 35%, 35%). The
trial was not specifically powered to detect interactions between
the intervention factors nor for subgroups.
Analysis
We used analysis of covariance for a factorial study for the main
continuous outcomes, baseline symptom severity, and potential
confounders as appropriate (in this case smoking was included
in the models as it is related to symptom severity). All results
presented also control for antibiotic prescribing strategy,
although the estimates were little altered. Cox regression was
used for the duration of symptoms (after we checked the
proportional hazards assumption) and logistic regression for
antibiotic use and reconsultation. Odds ratios were converted
to risk ratios with standard formulas.20 We present the “main
effects” of each factor with 95% confidence intervals as we did
not find significant interactions. The primary analysis was
intention to treat with complete data (that is, no matter whether
patients complied, their data were analysed according to
randomisation group) with no imputation of missing data. The
trial management group defined important subgroups of interest
in advance of the analysis (but not at study inception): a per
protocol analysis for analgesics (that is, patients taking the
correct analgesics); patients with lower respiratory tract infection
(with a longer course of more severe illness)16; patients with
otitis media (a more painful illness)4; baseline severity of
symptoms above the median; baseline temperature 37.5°C or
above21; previous duration longer than the median; and children
(age ≤16). For temperature control we also specified the
subgroup of patients who reported fever in the previous 24
hours. As part of responding to referees we also checked for
interactions according to older age (age ≥60) and previous lung
problems. For the clinical subgroups evidence of effectiveness
in subgroups was agreed as requiring both a significant
interaction term and significant estimates when the subgroup
was selected. No interim analyses were performed.
Results
From 3March 2010 to 28 March 2012, 53 general practitioners
and practice nurses recruited 889 patients in 25 practices
(figure)⇓. Baseline characteristics were similar in all groups
(table 1⇓) and similar for those for whom follow-up data were
available (see table B in appendix). All patients were followed
up for one month; further follow-up after the initial month was
0.84 years (SD 0.36) and was similar in all groups. The diary
symptom severity scale had acceptable internal reliability for
days two to four (Cronbach’s α 0.72 for day two, 0.79 for day
three, and 0.79 for day four) and was sensitive to change over
the week (standardised response mean 1.60). Non-recruitment
logs were poorly completed by general practitioners.
The non-recruitment questionnaire had responses from 20
respondents who recruited most (n=704) of the patients. The
top reason (given by 14 recruiters) for eligible patients declining
was that the patient was too busy or insufficiently interested,
followed by concern about the proposed drug, then by the patient
being too unwell. The top reason given for not approaching
eligible patients (given by 18/19 recruiters) was insufficient
time.
Attrition bias
The characteristics of patients in whom the primary outcome
was not documented were similar to those followed up (n=751)
for baseline symptom score (1.0 v 0.98, respectively) , female
sex (82/136 (60%) v 458/744 (62%)), age ≤16 (31/136 (23%)
v 200/744 (27%)), diagnosis of lower respiratory tract infection
(22/135 (16%) v 113/742 (15%)) or diagnosis otitis media
(16/134 (12%) v 66/740 (9%)).
Performance bias: compliance during first
three days
From the main diary data for paracetamol use, patients took a
mean of 4.2 doses a day for the first three days in the
paracetamol group, 3.5 in the combined group, and 0.4 in the
ibuprofen group. For ibuprofen, patients took a mean of 0.3
doses in the paracetamol group, 2.9 in the ibuprofen group, and
2.7 in the combined group. Steam inhalation was reported a
mean of 1.6 times a day in the steam group for days two and
three and 0.1 times in the no steam group. Advice to use
analgesic regularly compared with as required made little
difference to the amount of analgesia used for either paracetamol
(2.8 doses v 2.4 doses) or ibuprofen (2.0 doses v 1.9 doses).
Symptom control: main results
There were no interactions between interventions (see appendix
for details). Overall, compared with advice to use paracetamol
alone, alternative advice on analgesia made little difference to
symptom severity (ibuprofen 0.04, 95% confidence intervals
−0.11 to 0.19; combined 0.11, −0.04 to 0.26) (table 2⇓). There
was also no effect of steam (table 3⇓) and no effect of advice
on regular compared with as required dosing (see appendix table
A), and the per protocol analysis produced similar results.
Primary outcome: subgroups
There were no significant interactions for subgroups defined by
the trial team except for lower respiratory tract infection and
for children (see appendix for details) nor for subgroups
suggested during the review process (age ≥60, previous lung
problems). When we selected the lower respiratory tract
infection subgroup, the estimate of benefit was a reduction of
0.40 (95% confidence interval −0.78 to −0.01) in symptom
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severity for the ibuprofen group and 0.47 (−0.84 to −0.10) for
the combined group (table 2⇓), roughly equivalent to one person
in two rating their symptoms a slight rather than a moderately
bad problem. When we selected the subgroup of patients aged
≤16, the benefit from ibuprofen in symptom severity again a
reduction of 0.47 (−0.76 to −0.18). Those aged over 16 might
even have less good symptom control (table 2), although the
effect was small.
Harms
The main harm anticipated from analgesic use was with
ibuprofen: abdominal side effects or wheeze in individuals with
undetected asthma. Themain diary was the only source of these
data, but there was little evidence of these anticipated harms
from ibuprofen, with similar figures in all groups (table 4)⇓).
There were no other harms reported for the drug components,
either by participants or based on notes review. The main harm
anticipated from steam inhalation was mild scalding: this was
reported by four of the 207 (2%) patients in the steam group
who provided usable symptom data from the full diary, but this
was not severe enough to require a consultation. Tables 5 and
6 show effectiveness of advice on analgesia and steam on other
outcomes.⇓⇓ Return with new or unresolved symptoms or
complications occurred in 12% of the paracetamol group but
were more common with ibuprofen (20%) or the combination
(17%) table 5⇓). Most of the 17 “complications” recorded were
not serious, and three could be classified as reconsultations
based on the baseline case record form: two in the paracetamol
group (one cellulitis, one otitis media); 11 in the ibuprofen group
(one quinsy, three sinusitis, one meningitis, one pneumonia,
three new cases of otitis media, and two reconsultations with
otitis media); and four in the combined group (one quinsy, one
new case of sinusitis, one reconsultation with sinusitis, one
cervical adenitis).
Discussion
Principal findings
In this pragmatic randomised factorial trial in patients with
respiratory tract infections in primary care, patients gained no
benefit from advice to use ibuprofen alone or a combination of
ibuprofen and paracetamol nor advice to use regular (rather than
as required) analgesia or steam inhalation. Patients with chest
infections and/or children probably did get more symptomatic
relief from ibuprofen alone, but this must be balanced against
possible modest harms—an increase in return visits with new
symptoms, unresolved symptoms, or a complication, although
most complications were not serious.
Strengths and weaknesses
To our knowledge this is the largest trial to date assessing the
impact of analgesic/antipyretic use and steam inhalation on
control and progression of symptoms. The patient groups were
broadly defined with a range of respiratory infections so the
increased variance in outcome measures makes type II error
more likely. The primary outcome (symptom severity in the
first few days), however, should be applicable in all acute
infections and was reasonably reliable and sensitive to change
in these patients. Recruitment was slow considering the
incidence of respiratory infections, but feedback during and
after the study made it clear that this study was easy to recruit
to, and the limit to recruitment was time pressures in busy winter
clinics, as in previous studies,15 16 confirmed by the end of study
questionnaire, hence non-recruitment logs were poorly
completed. This raises questions of generalisability, though
there was no evidence that the patients with more severe
symptomswere excluded as comparisonwith recent large simple
observational studies and trials shows that, if anything, our
included patients were slightly more severely affected (on a 0-3
scale, the mean severity for sore throat at baseline was 2.4 in
the current study versus 2.0 in the DESCARTE study; for cough
was 2.6 in the current study versus 2.2 in GRACE studies18 22).
Type I error is a possibility, particularly for the subgroup
analyses that were not specified at study inception, but
subgroups were defined before we performed the analysis, and
there were highly significant interactions for two significant
subgroups. Although the factorial design allowed us to explore
possible interactions between interventions, we did not power
this study specifically to detect interactions between the factors;
the sample sizes should have been sufficient to detect
interactions of the order of 0.5 of a standardised effect size (that
is, moderate and equivalent to one out of two symptoms being
rated a slight rather than a moderate effect). The results
controlled for potential confounders, but as estimates were not
meaningfully altered, the impact of confounding is likely to be
limited. This was a pragmatic study so patients were free not
to comply with advice, but in fact compliance was reasonably
good, except that there was little impact of advising patients to
take analgesics regularly. The consent process (where patients
were asked to use the strategy they would be randomised to)
and the information sheets provided are likely to provide higher
compliance thanwould occur in everyday practice. The grouping
of diagnostic categories (such as chest infections) was based on
previous definitions of lower respiratory tract infections18 23
applied to general practitioners’ recording of the diagnosis or
problem in the case record form, but diagnostic labels are likely
to be variable.
Results in context of other studies
There was no effect of either dosing advice or advice to inhale
with steam on symptom severity—neither the estimates nor the
lower confidence limits reached the defined level for clinical
significance—and no intervention modified antibiotic use.
Patients with uncomplicated lower respiratory infections were
more likely to benefit from advice to use ibuprofen, and a recent
trial showed that ibuprofen was as effective or possibly more
effective than antibiotics (Carl Llor, personal communication).
Children might also selectively benefit from ibuprofen. Those
aged 17 and over had slightly worse symptom control with
ibuprofen, although the effect was small and did not reach the
threshold for clinical significance. We could not show
superiority of the combined strategy, unlike a previous trial in
children,11 but our trial had a pragmatic open design and was
not an efficacy study, which is more likely to provide realistic
estimates of effectiveness in daily practice. We could not
confirm any benefit for temperature control either overall or in
subgroups of patients with a higher temperature, unlike a
previous efficacy trial in children.5 This could be because our
trial population was much less selected and we used a broader
measure (mean temperatures for three days) rather than time to
fever resolution.
The main harmwith ibuprofen seemed not to be gastrointestinal
side effects but an increased likelihood of reconsultation with
new or non-resolving symptoms. Most complications were not
serious and were mainly self limiting, but there were three more
serious complications in the ibuprofen group (pneumonia,
meningitis, and quinsy). Although there is concern that
interfering with fever can inhibit the immune response, a
Cochrane review found insufficient evidence of adverse events
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to confirm or refute the concern.9 Previous observational
studies24 25 have shown an association between ibuprofen use
and the development of necrotising fasciitis in children with
chicken pox, which could possibly be mediated by impaired
neutrophil function induced by non-steroidal anti-inflammatory
drugs. The ibuprofen use in the latter studies, however, could
equally have been a proxy marker for more severe illness.
Although the finding of increased reconsultation could have
been caused by chance, there was a similar effect of borderline
significance in the combined group and adjustment for possible
confounders did not modify the effect, so the possibility of
modest harm with ibuprofen should probably not be dismissed.
There was no evidence that steam inhalation provided
symptomatic benefit, and this study was much larger than the
combined studies in the Cochrane review, which showedmodest
benefit.13 We also recorded a few cases in which mild thermal
injury was reported, which supports previous concerns about
scalding,14 although there was no evidence of scalding severe
enough to require a consultation.
Implications for clinicians
Clinicians should probably not advise patients to use steam
inhalation in daily practice as it does not provide symptomatic
benefit for acute respiratory infections and a few individuals
are likely to experience mild thermal injury. Similarly, routinely
advising regular rather than as required analgesia is also not
likely to be effective. For most patients, clinicians should not
offer ibuprofen rather than paracetamol as there is little benefit,
but they could consider ibuprofen use in patients with chest
infections and those aged <16 who might selectively benefit.
Clinicians and patients need to balance any benefit from using
ibuprofen against the possible harm of increasing reconsultations
with poorly controlled symptoms and a small risk of
complications.
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What is already known on this topic
Ibuprofen is probably more effective for fever resolution in children than paracetamol alone, and the combination of both is also probably
marginally better than either alone
The effects are modest, however, and it is not clear whether overall symptom control is improved and whether the existing evidence
applies in typical primary care settings where patients probably have milder infections than those in secondary care
The evidence for steam inhalation is limited both for benefits and for harms
What this study adds
Advice to use steam inhalation or ibuprofen rather than paracetamol or advice to use regular rather than as required dosing are unlikely
to help most patients with acute respiratory tract infections
Advice to use ibuprofen might help short term symptom control for patients with chest infections and children but must be balanced
against the possible progression of symptoms during the next month in a minority of patients
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Tables
Table 1| Baseline characteristic of groups of patients with acute respiratory tract infections according to randomised treatment advice.
Figures are numbers* (percentage) of patients unless otherwise specified
SteamNo steamDrug taken regularlyDrug taken as requiredBothIbuprofenParacetamol
7.6 (7.0)7.4 (7.1)7.6 (7.9)7.4 (6.2)7.2 (6.5)7.3 (6.7)8.0 (7.9)Mean (SD) previous duration of illness
(days)
1.0 (0.44)1.0 (0.45)1.0 (0.46)1.0 (0.44)1.0 (0.44)1.0 (0.46)1.0 (0.44)Mean (SD) severity (all symptoms)
241/427 (56)287/453 (63)260/437 (60)268/443 (61)166/285 (58)182/291 (62)180/304 (59)Fever in previous 24 hours
70/376 (19)65/401 (16)65/389 (17)70/388 (18)50/254 (20)47/260 (18)38/263 (14)Lower respiratory infection (LRTI)†
42/422 (10)40/453 (9)39/434 (9)43/441 (10)29/283 (10)26/290 (9)27/302 (9)Otitis media†
75/425 (18)69/452 (15)65/434 (15)79/443 (18)40/284 (14)48/293 (16)56/300 (19)Previous lung problems
250/427 (59)290/453 (64)271/437 (62)269 /444 (61)160/285 (56)185/291 (64)195/304 (64)Sex (female)
77/427 (18)83/452 (18)88/437 (20)72/442 (16)55/285 (19)57/290 (20)48/304 (16)Current smoker
32 (22)35 (21)33 (22)34 (21)33 (22)34 (21)34 (21)Mean (SD) age (years)
*Denominators vary because of missing data.
†LRTI and otitis media based on diagnosis/symptoms recorded by general practitioner in CRF=case report form.
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Table 2| Effectiveness of advice strategies for analgesia on symptom control in patients with acute respiratory tract infections. Figures
are crude mean symptom severity scores two to four days after seeing doctor
Paracetamol and ibuprofenIbuprofen
Paracetamol
crude mean (SD)
Adjusted difference (95%
CI), P valueCrude mean (SD)
Adjusted* difference (95%
CI), P valueCrude mean (SD)
0.11 (−0.04 to 0.26), 0.141.78 (0.94)0.04 (−0.11 to 0.19), 0.591.71 (0.96)1.67 (0.82)Whole cohort
(n=743)
−0.47 (−0.84 to −0.10), 0.011.74 (0.84)−0.40 (−0.78 to −0.01), 0.041.70 (0.94)2.14 (0.99)LRTI (n=113)
0.20 (0.03 to 0.36), 0.031.77 (0.96)0.11 (−0.05 to 0.27), 0.191.73 (0.97)1.60 (0.77)Non-LRTI (n=630)
−0.04 (−0.31 to 0.23), 0.771.61 (0.90)−0.47 (−0.76 to −0.18), <0.011.20 (0.79)1.74 (0.80)Age ≤16 (n=200)
0.16 (−0.02 to 0.34), 0.081.85 (0.95)0.20 (0.03 to 0.38), 0.021.88 (0.96)1.65 (0.83)Age ≥17 (n=543)
*Adjusted for baseline symptom severity, dosing, steam, antibiotic prescribing, and smoking (as smoking significantly predicted symptom severity). Outcome is
severity of symptoms so lower symptom severity (or negative change) is better. Denominators vary because of missing data.
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Table 3| Effectiveness of advice strategies for steam inhalation for symptom control (symptom severity in two to four days after seeing
doctor) in patients with acute respiratory tract infections
Adjusted* difference (95% CI), P value
Crude mean (SD)
SteamNo steam
−0.02 (−0.14 to 0.10), 0.751.70 (0.90)1.74 (0.92)Whole cohort (n=743)
0.03 (−0.27 to 0.33), 0.861.75 (0.90)1.93 (0.96)LRTI (n=113)
−0.01 (−0.14 to 0.13), 0.931.68 (0.89)1.71 (0.91)Non-LRTI (n=630)
0.08 (−0.14 to 0.31), 0.461.57 (0.92)1.49 (0.79)Age ≤16 (n=200)
−0.06 (−0.20 to 0.09), 0.441.75 (0.89)1.82 (0.94)Age ≥17 (n=543)
*Adjusted for baseline symptom severity, dosing, steam, antibiotic prescribing, and smoking (as smoking significantly predicted symptom severity). Outcome is
severity of symptoms so lower symptom severity (or negative change) is better. Denominators vary because of missing data.
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Table 4| Reported harms associated with interventions for respiratory tract infections. Figures are numbers (percentage) of patients
CombinedIbuprofenParacetamol
16/134 (12)20/150 (13)29/150 (19)Diarrhoea
18/135 (13)16/149 (11)23/150 (15)Vomiting
42/132 (32)39/147 (27)39/149 (26)Abdominal pain
9/134 (7)10/149 (7)6/150 (4)Skin rash
52/134 (39)59/152 (39)56/150 (37)Wheeze
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Table 5| Effectiveness of advice strategies for analgesia on other outcomes in patients with acute respiratory tract infections
Paracetamol and ibuprofenIbuprofen
Paracetamol
crude data
Adjusted* statistic (95%
CI), P valueCrude mean (SD)
Adjusted* statistic (95%
CI), P valueCrude data
−0.07† (−0.20 to 0.06),
0.271
36.6 (0.5)0.07† (−0.06 to 0.19),
0.301
36.6 (0.6)36.6 (0.6)Crude mean (SD) temperature
days 2-4 (n=439)
0.98‡ (0.80 to 1.20), 0.8534 (3 to 7)0.97‡ (0.79 to 1.19), 0.7684 (3 to 7)4 (3 to 7)Crude median (25-7th centile)
duration of symptoms rated
moderately bad or worse
(n=722)
1.02§ (0.83 to 1.21), 0.803140/239 (59)0.99§ (0.79 to 1.17), 0.891145/254 (57)145/251 (58)No (%) using antibiotic (n=736)
1.49§ (0.98 to 2.18), 0.05848/285 (17)1.67§ (1.12 to 2.38), 0.01258/295 (20)35/300 (12)No (%) reconsultation (with new
or unresolved symptoms or
complications within 1 month)
0.90§ (0.74 to 1.02), 0.123100/129 (78)0.95§ (0.80 to 1.05), 0.384112/138 (81)116/138 (84)No (%) who believe in
effectiveness of antibiotics
1.02§ (0.86 to 1.10), 0.79177/88 (88)1.00§ (0.84 to 1.09), 0.98683/97 (86)82/96 (85)No (%) very satisfied with
consultation
*Models all controlled for baseline symptom severity, dosing, steam, antibiotic prescribing and smoking; duration model also controlled for previous duration of
illness; temperature model also controlled for baseline temperature; model for return with unresolved symptoms also controlled for initial diagnosis. Denominators
vary because of missing data.
†Adjusted difference.
‡Hazard ratio.
§Risk ratio.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f6041 doi: 10.1136/bmj.f6041 (Published 25 October 2013) Page 11 of 13
RESEARCH
Table 6| Effectiveness of advice strategies for steam inhalation on other outcomes in patients with acute respiratory tract infections
Adjusted* statistic (95% CI), P valueSteamNo steam
0.05† (−0.05 to 0.16), 0.3236.6 (0.6)36.6 (0.6)Crude mean (SD) temperature days 2-4 (n=439)
1.04‡ (0.89 to 1.23), 0.614 (3 to 7)4 (3 to 7)Crudemedian (25-7th centile) duration of symptoms
rated moderately bad or worse (n=722)
0.90§ (0.74 to 1.06), 0.211198/351 (56)232/393 (59)No (%) using antibiotic (n=736)
1.10§ (0.79 to 1.51), 0.5572/427 (17)69/453 (15)No (%) reconsultation (with new or unresolved
symptoms or complications within 1 month)
0.98§ (0.87 to 1.05), 0.61149/185 (81)179/220 (81)No (%) who believe in effectiveness of antibiotics
0.95§ (0.79 to 1.05), 0.41107/127 (84)135/154 (88)No (%) very satisfied with consultation
*Models all controlled for baseline symptom severity, dosing, steam, antibiotic prescribing, and smoking; duration model also controlled for previous duration of
illness; temperature model also controlled for baseline temperature; model for return with unresolved symptoms also controlled for initial diagnosis. Denominators
vary because of missing data.
†Adjusted difference.
‡Hazard ratio.
§Risk ratio.
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Figure
Flow and randomisation of participants. *Figures based on general practitioners’ reports
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